Alto Neuroscience Inc. (ANRO) Dividend History

Company News

• Alto Neuroscience Adds 'Intriguing' Depression Asset Via Over $100 Million Deal

  Alto Neuroscience acquired a portfolio of dopamine agonist drug combinations for treatment-resistant depression from Chase Therapeutics, including the advanced program ALTO-207, which showed significant improvements in depression symptoms in a Phase 2a trial.

  Benzinga
• ANRO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Alto Neuroscience, Inc. and Encourages Investors to Contact the Firm

  Alto Neuroscience, Inc. announced that its Phase 2b study of ALTO-100 in patients with major depressive disorder did not meet its primary endpoint, causing a nearly 60% drop in the company's stock price.

  GlobeNewswire Inc.
• Treatment Patch For Schizophrenia: Newly Listed Alto Neuroscience Is Uniquely Positioned In Neuropsychiatry Landscape

  Recently listed Alto Neuroscience Inc (NYSE:ANRO) released results from its healthy volunteer Phase 1 study of ALTO-101, a novel PDE4 inhibitor in development for cognitive impairment associated with schizophrenia (CIAS).  Results from the study demonstrated favorable tolerability and improved pharmacokinetics of ALTO-101 when administered via a transdermal delivery system (TDS or a patch) compared to oral administration.  The drug exposure levels achieved with the transdermal formulation were significantly greater than systemic exposure with oral administration while also reducing typical class-wide adverse events.  The company plans to initiate a proof-of-concept study evaluating ALTO-101 in patients with CIAS in the first half of 2024, with topline data expected in the second ...Full story available on Benzinga.com

  Benzinga
• Alto Neuroscience (ANRO): Strong Industry, Solid Earnings Estimate Revisions

  Alto Neuroscience (ANRO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

  Zacks Investment Research
• Wall Street hungry for IPO of Mexican supermarket chain BBB Foods as stock rises 9%

  BBB Foods’ stock rises in its first day of trading as IPO market churns out deals.

  MarketWatch

  Featured Companies: GUTS KYTX PMNT TBBB